Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 May;166(7-8):227-35.
doi: 10.1007/s10354-016-0450-5. Epub 2016 May 3.

Endocytosis in gene therapy with non-viral vectors

Affiliations
Review

Endocytosis in gene therapy with non-viral vectors

Aritz Perez Ruiz de Garibay. Wien Med Wochenschr. 2016 May.

Abstract

Gene therapy or the delivery of genetic material can be carried out not only with viral vectors, but with non-viral vectors too. Although the use of non-viral carriers is safer, this approach has generally been poorer in terms of transfection efficiency. In order to improve the transfection rates, it is important to exactly know the path that the nanoparticles go through. In this way, we can understand the reason why some of these vectors fail or are successful in their duties. This review aims to summarize the different stages and barriers that nanocarriers have to overcome during endocytosis so as to reach the cytoplasm, in the case of RNA, or the nucleus, in the case of DNA. In addition, different strategies that could be employed to improve the success of the carriers in each stage are suggested.

Keywords: DNA; Endocytosis; Gene therapy; Nanoparticles; Non-viral vectors; RNA.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Crit Rev Ther Drug Carrier Syst. 2004;21(2):67-95 - PubMed
    1. Mol Ther. 2006 Nov;14(5):745-53 - PubMed
    1. Cell Res. 2010 Mar;20(3):256-75 - PubMed
    1. Gene Ther. 2000 Mar;7(5):401-7 - PubMed
    1. Pharm Res. 2006 Mar;23(3):447-59 - PubMed

LinkOut - more resources